Funding for this research was provided by:
National Key Research and Development Program of China (2022YFC2704205)
Natural Science Foundation of China (82073647, 82373674)
Natural Science Foundation of China (82103914)
Outstanding Scientific Fund of Shengjing Hospital (Outstanding Scientific Fund of Shengjing Hospital)
345 Talent Project of Shengjing Hospital of China Medical University (345 Talent Project of Shengjing Hospital of China Medical University)
Scientific Research Project of Education Department of Liaoning Province (LJKMZ20221137)
Article History
Received: 12 August 2024
Accepted: 11 March 2025
First Online: 19 March 2025
Declarations
:
: The PLCO trial was approved by the Institutional Review Board of the National Cancer Institute and was carried out following the rules of the Declaration of Helsinki. All participants gave their informed consent for inclusion before they participated in this trial.
: There are no conflicts of interest to declare.